查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1950447

冠状动脉介入器材市场（依产品类型、输送系统、应用、销售管道和最终用户划分），全球预测，2026-2032年

Coronary Interventional Devices Market by Product Type, Delivery System, Application, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，冠状动脉介入器材市场价值将达到 194.5 亿美元，到 2026 年将成长至 207.3 亿美元，到 2032 年将达到 288.5 亿美元，复合年增长率为 5.79%。

关键市场统计数据
基准年 2025 194.5亿美元
预计年份：2026年 207.3亿美元
预测年份 2032 288.5亿美元
复合年增长率 (%) 5.79%

本文简明扼要地描述了临床需求、人口老化和手术创新如何重塑冠状动脉介入治疗的需求、器械设计和治疗路径。

冠状动脉介入治疗器材是现代冠状动脉阻塞性疾病患者医疗照护的基础，它们提供直接的机械和药物解决方案，以恢復灌注并降低缺血风险。这些技术涵盖支架、球囊导管和各种动脉粥状硬化斑块切除术系统，每种器械根据病变类型、血管大小和手术策略发挥不同的作用。随着临床医生追求更微创、更持久的治疗方法，器械的性能、输送性和与辅助影像和药物治疗的兼容性对于决定手术成功和患者的长期预后至关重要。

技术进步、不断变化的医疗服务环境以及循证监管要求如何融合，正在重新定义医疗器材的开发和应用路径

冠状动脉介入治疗领域正经历变革，这主要得益于技术的成熟、医疗服务模式的转变以及临床医生期望的不断提高。在技​​术方面，药物释放型支架平台不断改进聚合物化学、药物释放动力学和支架几何结构，以平衡径向强度和内皮修復。同时，人们对生物可吸收概念和药物涂层球囊的兴趣日益浓厚，推动了新的临床研究和特定领域的应用，特别是在血管保护和血管再阻塞驱动因素需要替代方法的领域。这些器材层面的变革与术中成像技术和生理评估技术的进步相辅相成。高解析度成像和生理引导的工作流程正被越来越多地用于优化器械的选择和部署，从而降低手术操作的变异性。

评估2025年关税对冠状动脉介入器材生态系供应链、筹资策略和製造投资决策的影响

预计在2025年前后实施的关税政策，为冠状动脉介入器材产业的筹资策略、采购计画和定价决策引入了新的成本因素。进口关税和协调关税分类的变更影响了包括特殊合金、聚合物和精密工程导管零件在内的多种器械组件，给依赖全球一体化供应链的製造商带来了即时的成本压力。为了因应这些变化，许多公司加快供应商多元化进程，探索近岸外包的机会，并考虑垂直整合方案，以降低进口关税和运输成本波动的风险。

深入分析产品、临床用户和分销管道的细分，以揭示不同设备组合的技术权衡、采用驱动因素和供应链影响。

了解产品和分销管道的细分，有助于揭示冠状动脉介入产品领域内临床需求、技术重点和商业性策略的交汇点。在支架领域，裸金属支架、生物可吸收血管支架和药物释放型支架之间的差异，反映了不同的研发重点。裸金属支架强调机械结构的简易性和成本效益，而生物可吸收支架则优先考虑暂时的血管支撑和最终的生物功能恢復。药物释放型支架则着重于药物与聚合物的相互作用以及合金的选择，其中钴铬合金、铂铬合金和不銹钢合金分别代表了输送性、径向强度和渗透性方面的权衡。同时，球囊导管的多样性——从传统球囊导管到切割球囊球囊导管、药物涂层球囊导管和折迭球囊导管——反映了针对病变形态进行工具优化，以及在钙化或血管再阻塞部位进行高效药物输送和斑块修饰的需求。

对医疗保健结构和报销环境的区域差异如何导致采用路径和商业化策略的差异进行策略性评估

区域趋势显着影响临床实务模式、报销机制以及技术应用的速度。在美洲，手术量和医生对先进经皮治疗方法的熟悉程度往往有利于高端技术的广泛应用，而整合的支付系统和大规模的综合医疗网络则推动了结构化的采购方式和基于价值的合约谈判。因此，该地区的市场参与企业正专注于可靠的临床数据、高效的服务模式以及与医院集团采购政策相符的伙伴关係。

对主要企业的策略重点进行深入分析，揭示研发投入、通路选择和供应链韧性如何塑造其竞争优势。

为了满足临床需求和应对竞争压力，业内相关人员正积极寻求结合针对性研发、策略联盟和生产优化等多种策略。领先的心臟器械公司致力于透过金属合金、聚合物科学和抗增殖剂的进步，提高支架输送性能、降低血栓形成风险并延长使用寿命。其他公司则透过整合影像平台，并为临床医生提供术前规划和术中决策支援的数位化工具，来完善其核心产品线。在产品创新的同时，多家公司正透过建立区域製造地和采用多种关键零件筹资策略，加大对供应链韧性的投入。

为商业、临床和供应链领导者提供实用建议，帮助他们将证据和韧性转化为永续的竞争优势。

产业领导者应优先采取一系列协作行动，以在控制营运风险的同时，充分发挥临床价值。首先，产品蓝图必须与已证实的临床需求和真实世界证据一致。这需要重点投资于註册登记和上市后监测，将设备特性与以患者为中心的疗效和卫生经济学终点联繫起来。其次，应透过对替代供应商进行资质认证、提高库存透明度以及探索区域製造伙伴关係关係来落实供应链多元化，从而降低关税和物流风险。第三，与临床医生和手术团队的密切合作必须超越初始应用阶段，涵盖全面的培训、指导和数位化支援工具，以提高手术流程的一致性和疗效。

采用透明的混合方法调查方法框架，结合临床医生访谈、监管数据和註册分析以及交叉检验的证据综合，为策略决策提供资讯。

本研究采用混合方法，整合冠状动脉介入领域的技术、临床和商业性见解。主要资料收集包括对介入性心臟病专家、采购主管和器材技术人员进行结构化访谈，以了解实际操作偏好、库存管理实务和未满足的临床需求。这些定性见解与监管申报文件、同行评审的临床试验和手术註册数据进行三角验证，以确保与已发表的证据一致，并识别新兴的实践模式。此外，采购和分销专家提供了有关合约、物流和海关相关影响的营运背景资讯。

对技术创新、临床参与和营运韧性如何整合以定义冠状动脉介入治疗市场未来成功进行综合分析

累积分析凸显了临床需求与快速创新之间的交会点，在此交会点上，器械设计、手术影像和输送模式共同决定了病患和购买者的价值。支架技术、辅助球囊和动脉粥状硬化斑块切除术的进步正在拓展临床医生可用的治疗手段，而区域和政策趋势则影响这些技术的应用速度和特点。在面临新兴关税挑战和不断变化的报销环境的背景下，供应链韧性和实证医学能力是至关重要的差异化因素。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 冠状动脉介入器材市场（依产品类型划分）

  • 冠状动脉支架
    • 裸金属支架
    • 药物涂层支架
    • 生物可吸收支架
    • 药物释放型支架
  • 球囊导管
    • 预扩张球囊
    • 扩张后球囊
    • 药物涂层球囊
    • 切割球囊和球囊导管
  • 导管导引线
    • 主力导管导引线
    • 支撑导管导引线
    • 特殊导管导引线
  • 导管
    • 引导管
    • 诊断导管
  • 血管通路及闭合装置
    • 导入鞘套
    • 止血瓣
    • 血管闭合装置
  • 斑块修饰装置
    • 动脉粥状硬化斑块切除术装置
    • 血管内碎石系统
  • 血栓切除术及栓塞保护装置
    • 吸食血栓清除装置
    • 机械血栓切除装置
    • 栓塞保护装置
  • 血流动力学辅助装置
    • 主动脉内球囊反搏泵
    • 经皮心室辅助装置
  • 影像和生理设备
    • 血管内超音波系统
    • 光同调断层扫瞄系统
    • 分数血流储备测量系统
    • 瞬时波形自由比率测量系统

9. 依输送系统分類的冠状动脉介入器材市场

  • 越过电线
  • 快速交换
  • 固定电线
  • 可转向系统
  • 鞘套系统

第十章：冠状动脉介入器材市场（依应用领域划分）

  • 稳定性冠状动脉疾病
  • 急性冠状动脉症候群
    • ST段上升型心肌梗塞
    • 非ST段上升型急性冠状动脉症候群
  • 慢性完全闭塞
  • 左主干病变
  • 分叉病变
  • 支架内血管再阻塞

第十一章：冠状动脉介入器材市场（依销售管道划分）

  • 直销
  • 透过分销商销售
  • 线上采购平台

12. 依最终使用者分類的冠状动脉介入器材市场

  • 医院
  • 心臟导管检查室
  • 门诊手术中心

13. 冠状动脉介入器材市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：冠状动脉介入器材市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国冠状动脉介入器材市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国冠状动脉介入器材市场

17. 中国：冠状动脉介入器材市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cardiovascular Systems, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Elixir Medical Corporation
  • Endologix LLC
  • iVascular SLU
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • QualiMed Innovative Medizinprodukte GmbH
  • Sahajanand Medical Technologies Limited
  • Shockwave Medical, Inc.
  • Siemens Healthineers AG
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-4F7A6D4FD86D

The Coronary Interventional Devices Market was valued at USD 19.45 billion in 2025 and is projected to grow to USD 20.73 billion in 2026, with a CAGR of 5.79%, reaching USD 28.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.45 billion
Estimated Year [2026] USD 20.73 billion
Forecast Year [2032] USD 28.85 billion
CAGR (%) 5.79%

A concise portrayal of how clinical needs, aging populations, and procedural innovation are reshaping demand, device design, and care pathways in coronary interventions

Coronary interventional devices form the backbone of contemporary care for patients with obstructive coronary artery disease, providing direct mechanical and pharmacologic solutions that restore perfusion and reduce ischemic risk. These technologies span stents, balloon catheters, and a spectrum of atherectomy systems, each playing a distinct role across lesion types, vessel sizes, and procedural strategies. As clinicians pursue less invasive, more durable interventions, device performance, deliverability, and compatibility with adjunctive imaging and pharmacotherapy have become central determinants of procedural success and longer-term patient outcomes.

Epidemiologically, the prevalence of coronary artery disease remains elevated in many middle- and high-income populations, driven by aging demographics and persistent cardiometabolic risk factors. Consequently, the procedural mix is evolving: there is greater emphasis on complex lesion management, including calcified and bifurcation disease, which increases the demand for specialized devices and hybrid approaches. Simultaneously, shifts in care settings-from inpatient catheterization laboratories toward ambulatory surgical centers-are influencing device selection, inventory models, and logistics. These converging clinical, demographic, and care-delivery trends set the stage for rapid innovation and strategic recalibration among device manufacturers, health systems, and distributors.

From a regulatory and clinical-evidence perspective, iterative enhancements in device materials, drug elution platforms, and scaffold constructs have lowered complication rates and expanded indication envelopes. Emerging imaging modalities and physiology-driven decision tools are reshaping procedural algorithms, prompting device makers to integrate compatibility and adjunctive support into product roadmaps. Taken together, these factors underscore a dynamic environment in which clinical efficacy, economic value, and supply chain resilience define competitive differentiation.

How converging technological advancements, care setting migration, and evidence-driven regulatory expectations are redefining device development and adoption pathways

The coronary interventional landscape is being transformed by a confluence of technological maturation, shifting care delivery models, and evolving clinician expectations. On the technology front, drug eluting stent platforms continue to refine polymer chemistry, drug-release kinetics, and strut geometry to balance radial strength with endothelial healing. Concurrently, interest in bioresorbable concepts and drug-coated balloons has stimulated new clinical investigations and niche adoption where vessel preservation or restenosis biology warrants alternative approaches. These device-level shifts are complemented by advances in intraprocedural imaging and physiologic assessment; high-resolution imaging and physiology-guided workflows are increasingly used to optimize device selection and deployment, thereby reducing procedural variability.

Care delivery transformations are equally consequential. The migration of lower-risk percutaneous procedures to ambulatory surgical centers and specialty clinics is altering device procurement cycles, inventory strategies, and sterile processing requirements. As a result, manufacturers and distributors must prioritize compact packaging, rapid order fulfillment, and training resources tailored to diverse clinical environments. In parallel, digital health innovations-ranging from procedure planning software to remote proctoring-are enabling virtual training and performance feedback loops that accelerate clinician adoption of new devices. This digital integration also supports post-market surveillance and real-world evidence generation, which in turn inform iterative product improvements.

Finally, regulatory expectations and payer scrutiny are influencing product development strategies. There is stronger emphasis on demonstrable value, long-term safety, and comparative effectiveness, driving manufacturers to invest in both rigorous clinical programs and longitudinal registries. Taken together, these transformative shifts are forging a more connected ecosystem in which technical innovation, evidence generation, and delivery-channel optimization co-evolve to define competitive advantage.

An assessment of how 2025 tariff measures reshaped supply chains, procurement strategies, and manufacturing investment decisions across the coronary device ecosystem

Tariff policy enacted in and around 2025 introduced new cost considerations that ripple through sourcing strategies, procurement planning, and pricing decisions in the coronary interventional device space. Import duties and changes in harmonized tariff classifications affected a range of device components, including specialized alloys, polymeric compounds, and precision-engineered catheter elements, creating immediate cost pressure for manufacturers reliant on globalized supply chains. In response, many firms accelerated supplier diversification, sought nearshoring opportunities, and examined vertical integration options to reduce exposure to import levies and shipping volatility.

Beyond direct input-cost effects, tariffs influenced partner negotiations and distribution economics. Distributors with long-standing contracts adjusted margin structures to accommodate higher landed costs, while health systems re-evaluated formulary choices in light of total cost of ownership. These dynamics encouraged some purchasers to favor devices with simplified supply chains or to negotiate bundled pricing that encompassed ancillary disposables. Moreover, tariffs affected innovation timelines: capital that might have funded incremental R&D or commercialization activities in low-margin product lines was redirected to securing supply continuity and manufacturing resilience.

Crucially, the policy environment also catalyzed strategic investments in domestic manufacturing capabilities and quality-system enhancements. Firms investing in local production faced higher upfront costs but gained shorter lead times and greater control over regulatory compliance and traceability. As a result, an important consequence of tariff-induced disruption was a reconfiguration of risk management priorities across the industry, with procurement resilience, supplier transparency, and operational flexibility moving to the top of executive agendas.

Deep dive into product, clinical-user, and distribution segmentation that clarifies engineering trade-offs, adoption drivers, and supply chain implications for device portfolios

Understanding product and channel segmentation reveals where clinical demand, engineering focus, and commercial effort converge within coronary interventional portfolios. In the stent arena, distinctions among bare metal stent, bioresorbable vascular scaffold, and drug eluting stent illuminate divergent development priorities: bare metal constructs emphasize mechanical simplicity and cost-efficiency, whereas bioresorbable scaffolds prioritize temporary vessel support and eventual restoration of native physiology; drug eluting stents concentrate on drug-polymer interactions and alloy choice, with cobalt chromium, platinum chromium, and stainless steel variants each representing trade-offs in deliverability, radial strength, and radiopacity. Meanwhile, balloon catheter diversity-ranging from conventional balloon catheter designs through cutting balloon catheter, drug coated balloon catheter, and scoring balloon catheter-reflects the need to tailor tools to lesion morphology and to optimize drug transfer or plaque modification in calcified or restenotic segments.

Complementing stents and balloons, the atherectomy system segment is defined by distinct mechanistic approaches: laser atherectomy system solutions ablate tissue with precision energy, orbital atherectomy systems modify calcific plaque through centrifugal sanding, and rotational atherectomy systems selectively remove hard plaque using high-speed burrs. These modalities are selected based on lesion calcification patterns, vessel tortuosity, and operator familiarity, which in turn influences training and capital equipment strategies. From a user perspective, differences among ambulatory surgical centers, hospitals, and specialty clinics drive procurement behavior, procedural throughput expectations, and inventory management. Ambulatory settings typically emphasize disposability, rapid turnover, and compact sterile inventories, while hospitals balance a broader device mix with integrated support services; specialty clinics occupy niche positions where highly specialized devices and expertise are concentrated.

Distribution channels-direct relationships, distributor partnerships, and online ordering pathways-also determine market reach and service models. Manufacturers relying on direct sales often invest heavily in clinical education and local field teams, whereas distributor networks provide broad geographic coverage and logistical scalability; online channels add convenience and traceability but require robust quality assurances and regulatory vetting. Taken together, these segmentation layers animate product strategy, clinical engagement, and commercial execution across the coronary interventional landscape.

A strategic appraisal of how distinct regional healthcare structures and reimbursement environments drive differentiated adoption paths and commercialization tactics

Regional dynamics shape clinical practice patterns, reimbursement realities, and the pace of technology adoption in notable ways. In the Americas, procedural volumes and physician familiarity with advanced percutaneous solutions tend to support broad uptake of premium technologies, while consolidated payer systems and large integrated delivery networks drive structured procurement approaches and value-based contracting discussions. As a consequence, market entrants in this region focus on robust clinical data, efficient service models, and partnerships that align with hospital group procurement preferences.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement pathways create a complex adoption landscape. While several European markets rapidly embrace evidence-backed innovations, other countries within the region prioritize cost-containment, which requires flexible pricing strategies and local reimbursement evidence. In addition, several nations within the region are implementing national registries and quality benchmarks that influence clinician adoption patterns and post-market surveillance expectations.

In Asia-Pacific, rising demand is propelled by expanding access to advanced cardiovascular care, increasing urbanization, and growing capacity in tertiary care centers. However, the region is not monolithic: advanced health systems in some economies demonstrate rapid uptake of next-generation devices, while emerging markets emphasize affordability and simplified logistics. Consequently, manufacturers pursuing Asia-Pacific expansion must calibrate product offerings to local clinical needs, regulatory timelines, and distribution capabilities, and they often combine clinical partnerships with localized training programs to build adoption momentum.

Insightful exploration of leading firms' strategic priorities showing how R&D focus, channel choices, and supply resilience are shaping competitive advantage

Industry participants are responding to clinical demand and competitive pressures through a combination of targeted R&D, strategic partnerships, and manufacturing optimization. Leading cardiac device companies have concentrated on enhancing stent deliverability, reducing thrombogenicity, and extending durability through advances in metallic alloys, polymer science, and antiproliferative agents. Others have supplemented core product lines by integrating imaging-compatible platforms and by supporting clinicians with digital tools for pre-procedural planning and intraoperative decision support. Parallel to product innovation, several firms have invested in supply-chain resilience by establishing regional manufacturing sites and by adopting multi-sourcing strategies for critical components.

Competitive dynamics also reflect differing go-to-market approaches. Some companies prioritize direct clinical engagement and long-term hospital partnerships, deploying dedicated field clinical specialists and robust training curricula to secure premium placements. Meanwhile, others leverage distributor networks and e-commerce channels to reach broader geographies and smaller care settings. Alliances between device manufacturers and technology firms are emerging, particularly in areas that link procedural devices with software-driven analytics and post-market surveillance capabilities. These collaborations aim to generate real-world evidence more efficiently and to support differentiated value propositions in reimbursement negotiations.

Collectively, company-level strategies reveal an industry balancing near-term operational resilience with longer-term innovation pipelines, translating scientific advances into reproducible clinical outcomes and scalable commercial models.

Action-focused recommendations for commercial, clinical, and supply-chain leaders to convert evidence and resilience into sustainable competitive advantage

Industry leaders should prioritize a set of coordinated actions to capture clinical value while managing operational risk. First, aligning product roadmaps with demonstrated clinical need and real-world evidence will be essential; this requires concentrated investment in registries and post-market studies that link device characteristics to patient-centered outcomes and health economic endpoints. Second, companies should operationalize supply-chain diversification by qualifying alternate suppliers, increasing inventory transparency, and exploring regional manufacturing partnerships to mitigate tariff and logistics risks. Third, close collaboration with clinicians and procedural teams must expand beyond initial product adoption to include comprehensive training, proctoring, and digital support tools that improve procedural consistency and outcomes.

Additionally, commercial teams should refine segmentation strategies to match distribution and pricing models with care settings-adapting packaging, service bundles, and procurement terms for ambulatory surgical centers, hospitals, and specialty clinics. Strategic partnerships with payers and health systems to develop outcome-based or bundled payment pilots can accelerate uptake for high-value technologies. Finally, leaders must invest in data capabilities that capture real-world performance, enabling iterative product improvements and stronger payer dialogues. By executing on these prioritized actions, organizations can strengthen clinical credibility, reduce exposure to external shocks, and accelerate sustainable growth.

A transparent mixed-methods research framework combining clinician interviews, regulatory and registry analyses, and cross-validated evidence synthesis to inform strategic decisions

The research adopted a mixed-methods approach to synthesize technical, clinical, and commercial insights across the coronary interventional domain. Primary data collection included structured interviews with interventional cardiologists, procurement leads, and device engineers to capture real-world procedural preferences, inventory practices, and unmet clinical needs. These qualitative inputs were triangulated with regulatory filings, peer-reviewed clinical trials, and procedural registry data to ensure alignment with published evidence and to identify emergent practice patterns. In addition, procurement and distribution experts provided operational context on contracting, logistics, and tariff-related impacts.

Analytical rigor was maintained through cross-validation of findings across multiple data sources, iterative hypothesis testing with subject-matter experts, and sensitivity checks where available. The methodology emphasized transparency in source attribution, explicit acknowledgment of regional heterogeneity, and a focus on outcome-relevant metrics rather than proprietary market sizing. Limitations include variable data granularity across regions and the evolving nature of regulatory decisions that may alter adoption timelines. To mitigate these constraints, the study prioritized longitudinal evidence and expert consensus to produce robust, actionable conclusions intended to inform strategic planning and operational decision-making.

Synthesis of how technological advances, clinical engagement, and operational resilience converge to define future success across coronary intervention markets

The cumulative analysis underscores a sector at the intersection of clinical necessity and rapid innovation, where device design, procedural imaging, and care-delivery models collectively determine value for patients and purchasers. Advances in stent technology, adjunctive balloons, and atherectomy modalities are expanding the armamentarium available to clinicians, while regional and policy dynamics shape the speed and character of adoption. Supply-chain resilience and evidence-generation capabilities have become decisive differentiators, particularly in an environment that includes new tariff considerations and variable reimbursement landscapes.

As the industry moves forward, successful stakeholders will be those who translate scientific progress into replicable clinical benefit, who align commercial models with diverse care settings, and who invest in resilient operations. Continuous engagement with clinicians, payers, and regulatory authorities will be essential to ensure that innovations meet both clinical and economic criteria for broad adoption. Ultimately, the path to sustained impact lies in pairing rigorous evidence with adaptable commercialization strategies that respect regional realities and evolving procedural practices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Interventional Devices Market, by Product Type

  • 8.1. Coronary Stents
    • 8.1.1. Bare Metal Stents
    • 8.1.2. Drug Eluting Stents
    • 8.1.3. Bioresorbable Scaffolds
    • 8.1.4. Drug Coated Stents
  • 8.2. Balloon Catheters
    • 8.2.1. Pre Dilatation Balloons
    • 8.2.2. Post Dilatation Balloons
    • 8.2.3. Drug Coated Balloons
    • 8.2.4. Cutting And Scoring Balloons
  • 8.3. Guidewires
    • 8.3.1. Workhorse Guidewires
    • 8.3.2. Support Guidewires
    • 8.3.3. Specialty Guidewires
  • 8.4. Catheters
    • 8.4.1. Guiding Catheters
    • 8.4.2. Diagnostic Catheters
  • 8.5. Vascular Access And Closure Devices
    • 8.5.1. Introducer Sheaths
    • 8.5.2. Hemostatic Valves
    • 8.5.3. Vascular Closure Devices
  • 8.6. Plaque Modification Devices
    • 8.6.1. Atherectomy Devices
    • 8.6.2. Intravascular Lithotripsy Systems
  • 8.7. Thrombectomy And Embolic Protection Devices
    • 8.7.1. Aspiration Thrombectomy Devices
    • 8.7.2. Mechanical Thrombectomy Devices
    • 8.7.3. Embolic Protection Devices
  • 8.8. Hemodynamic Support Devices
    • 8.8.1. Intra Aortic Balloon Pumps
    • 8.8.2. Percutaneous Ventricular Assist Devices
  • 8.9. Imaging And Physiology Devices
    • 8.9.1. Intravascular Ultrasound Systems
    • 8.9.2. Optical Coherence Tomography Systems
    • 8.9.3. Fractional Flow Reserve Systems
    • 8.9.4. Instantaneous Wave Free Ratio Systems

9. Coronary Interventional Devices Market, by Delivery System

  • 9.1. Over The Wire
  • 9.2. Rapid Exchange
  • 9.3. Fixed Wire
  • 9.4. Steerable Systems
  • 9.5. Sheathless Systems

10. Coronary Interventional Devices Market, by Application

  • 10.1. Stable Coronary Artery Disease
  • 10.2. Acute Coronary Syndromes
    • 10.2.1. ST Elevation Myocardial Infarction
    • 10.2.2. Non ST Elevation Acute Coronary Syndromes
  • 10.3. Chronic Total Occlusion
  • 10.4. Left Main Disease
  • 10.5. Bifurcation Lesions
  • 10.6. In Stent Restenosis

11. Coronary Interventional Devices Market, by Sales Channel

  • 11.1. Direct Sales
  • 11.2. Distributor Sales
  • 11.3. Online Procurement Platforms

12. Coronary Interventional Devices Market, by End User

  • 12.1. Hospitals
  • 12.2. Cardiac Catheterization Laboratories
  • 12.3. Ambulatory Surgical Centers

13. Coronary Interventional Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Coronary Interventional Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Coronary Interventional Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Coronary Interventional Devices Market

17. China Coronary Interventional Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AngioDynamics, Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Biotronik SE & Co. KG
  • 18.9. Boston Scientific Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. Cardiovascular Systems, Inc.
  • 18.12. Cook Medical LLC
  • 18.13. Edwards Lifesciences Corporation
  • 18.14. Elixir Medical Corporation
  • 18.15. Endologix LLC
  • 18.16. iVascular S.L.U.
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.19. Medtronic plc
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. MicroPort Scientific Corporation
  • 18.22. QualiMed Innovative Medizinprodukte GmbH
  • 18.23. Sahajanand Medical Technologies Limited
  • 18.24. Shockwave Medical, Inc.
  • 18.25. Siemens Healthineers AG
  • 18.26. Teleflex Incorporated
  • 18.27. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRE DILATATION BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY POST DILATATION BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY WORKHORSE GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUPPORT GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY GUIDEWIRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDING CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRODUCER SHEATHS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMOSTATIC VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ATHERECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR LITHOTRIPSY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ASPIRATION THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRA AORTIC BALLOON PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY INSTANTANEOUS WAVE FREE RATIO SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY OVER THE WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY RAPID EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY FIXED WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STEERABLE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SHEATHLESS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY STABLE CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY NON ST ELEVATION ACUTE CORONARY SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY LEFT MAIN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BIFURCATION LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IN STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ONLINE PROCUREMENT PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CARDIAC CATHETERIZATION LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY VASCULAR ACCESS AND CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PLAQUE MODIFICATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY AND EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY HEMODYNAMIC SUPPORT DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY IMAGING AND PHYSIOLOGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CORONARY STENTS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY GUIDEWIRES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CORONARY INTERVENTIONAL DEVICES MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 269. MID